Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.
Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC
23 Apr 2024
PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.
PAOLA-1 at 5 years: Maintenance olaparib + bevacizumab support long-term remission in HRD-positive ovarian cancer
22 Apr 2024
Anlotinib plus etoposide/carboplatin improves survival in extensive-stage SCLC
Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.
